Participating in the BIOGEN EMBARK Aducanumab and Long-Term Extension Clinical Trial: A Patient’s Journey

As a patient with Alzheimer’s disease, I have been fortunate enough to participate in the BIOGEN EMBARK Aducanumab clinical trial and its long-term extension. In this blog post, I’d like to share my experience and thoughts on the trials, including what motivated me to participate, the enrollment process, and the benefits of being involved.

Why I Decided to Participate

When I was diagnosed with Alzheimer’s several years ago, I was determined to do everything in my power to slow down its progression. I had heard that Advanced Memory Research Institute of NJ was conducting a clinical trial for people living with younger / early-stage Alzheimer’s disease. I was initially enrolled in the third stage of the BIOGEN Aducanumab clinical trial.  Subsequently I was enrolled in the BIOGEN EMBARK clinical trial for the investigational drug Aducanumab and was eager to learn more. After speaking with my doctor and researching the trial, I was convinced that it was the right choice for me.

The Enrollment Process

Enrolling in the BIOGEN EMBARK trial was a smooth process. The trial staff were knowledgeable and informative, answering all of my questions and providing guidance throughout the enrollment process. I underwent several tests to determine my eligibility, including a medical history review, physical exams, and cognitive assessments.

Trial Participation

Once I was enrolled in the EMBARK trial, I received the investigational drug every four weeks through an IV infusion. I also had regular visits with the trial staff to monitor my condition and assess the drug’s effects. During these visits, I underwent cognitive assessments, physical exams, and MRI scans.

After completing the initial trial, I was given the opportunity to continue participating in the long-term extension, which I did eagerly. This allowed me to receive continued treatment with Aducanumab and continue to be closely monitored by the trial staff.

My Thoughts on the Experience

Participating in the original trial, the EMBARK trial and its long-term extension has been a life-changing experience. It has given me hope and a sense of purpose, knowing that I am contributing to the advancement of Alzheimer’s research. The trial staff have been incredibly supportive and have made the process as easy as possible.

I am grateful for the opportunity to receive continued treatment with Aducanumab and for the close monitoring I have received throughout the trial. The cognitive assessments and regular check-ins have provided me with a sense of reassurance and have helped me to stay informed about my condition.

In conclusion, participating in a clinical trial, particularly one with a long-term extension, can be a valuable experience for patients with Alzheimer’s. It offers the opportunity to contribute to research, receive continued treatment, and receive close monitoring and care. If you or a loved one is living with Alzheimer’s, I encourage you to consider participating in a clinical trial.